Kenya’s marathon champion Peres Jepchirchir gets three-year ban for doping
Kenya's Peres Jepchirchir, the reigning world marathon champion and 2021 Tokyo Olympic gold medalist, has been banned for three years after testing positive for the banned blood booster EPO, the Athletics Integrity Unit said. One report states that her victory at the 2026 Sydney Marathon has also been stripped from her record.
Written by CRAYON from the outlets' reports below.Coverage 3 sources · 2 independent (wire copy collapsed) · 6 reports · 1L2C
Chronological — read the same story from every side and decide for yourself.
-
Olympic marathon champion Peres Jepchirchir hit with a 3-year ban after EPO test
MONACO (AP) — World and former Olympic marathon champion Peres Jepchirchir has been suspended for three years over a positive drug test for the banned substance EPO, the Athletics Integrity Unit said Thursday.Jepchirchir won women’s marathon gold at the Tokyo Olympics in 2021 and the world title last year.
-
World marathon champion Peres Jepchirchir banned for three years over anti-doping violation
Jepchichir tested posted for the blood booster EPO and has had her victory at the 2026 Sydney Marathon stripped from her record
-
World marathon champion Jepchirchir gets three-year doping ban
Reigning world marathon champion Peres Jepchirchir is banned for three years for a doping violation.
1 syndicated copy — also ran in Yahoo Sports
-
Olympic marathon winner Jepchirchir suspended for doping
Olympic marathon champion Peres Jepchirchir of Kenya has been suspended for three years for doping, the Athletics Integrity Unit (AIU) said in a statement. Jepchirchir won the gold medal at the 2021 Olympic Games in Tokyo.
-
Kenya’s marathon champion Peres Jepchirchir gets three-year ban for doping
Jepchirchir breached anti-doping rules by testing positive for banned substance EPO, Athletics Integrity Unit says.
-
Peres Jepchirchir, Olympic marathon gold medalist, suspended 3 years in doping case
Peres Jepchirchir tested positive for banned blood booster EPO in July.
Discussion 0 comments